Its ability to target mainly the IL-6/STAT3 pathway and downstream anti-apoptotic, EMT and cell cycle proteins, suggest its viability as part of the therapeutic armamentarium for CC. The gene discussed is STAT3; the disease is cholangiocarcinoma.